Abstract
Efficacy and safety of ravulizumab in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: outcomes from the phase 3 CHAMPION-NMOSD trial (S5.002)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have